HMP has assembled a leading drug research and development team (R&D) of over 360 scientists and staff based in China, which collectively form the Innovation Platform of Hutchison China MediTech (AIM/NASDAQ: HCM). The large-scale, in-house and fully-integrated R&D operations work seamlessly together to discover and develop targeted therapies for oncology and immunology diseases.
Chemistry-focused R&D approach
HMP uses a chemistry-focused approach to develop highly selective small molecule tyrosine kinase inhibitors that are intended to have potentially global first-in-class efficacy or be sufficiently differentiated to be global best-in-class, next-generation therapies with a superior profile compared to existing approved drugs that act against the relevant kinase targets.
This approach consists of two main pillars:
- Developing synthetic compounds against novel targets with global first-in-class potential, which includes savolitinib (targeting c-Met), HMPL-523 (targeting Syk) and HMPL-453 (targeting FGFR1/2/3); and
- Developing synthetic compounds against validated targets with clear differentiation to potentially be a global best-in-class/next-generation therapy in their respective categories, including fruquintinib (targeting VEGFR1/2/3), sulfatinib (targeting VEGFR / FGFR1), epitinib (targeting EGFRm+ brain metastasis), theliatinib (targeting EGFR wild type) and HMPL-689 (targeting PI3K).
We have built up a broad and diversified pipeline of drug candidates , deliberately engineered to achieve:
- Unique selectivity to limit target-based toxicity
- High potency to optimise the dose selection with the objective to lower the required dose and thereby limit compound-based toxicity
- Chemical structures engineered to improve drug exposure in the targeted tissue
- The ability to be combined with other therapeutic agents
All differentiated drug candidates have advanced into the clinic and are currently in development in China and globally.